CZGZF yields 1.57% · JNJ yields 2.13%● Live data
📍 CZGZF pulled ahead of the other in Year 1
Combined, CZGZF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CZGZF + JNJ for your $10,000?
Colt CZ Group SE, together with its subsidiaries, engages in the production, purchase, and sale of firearms, ammunition products, and tactical accessories in the Czech Republic, the United States, rest of Europe, Africa, Asia, and internationally. Its firearms include pistols, revolvers, rifles, submachine guns, grenade launchers, machine guns, sniper rifles, shotguns, and centrefire rifles; and components for firearms comprising sights, optical mounting solutions, triggers, stocks, grips, and spare parts. The company also offers tactical and ballistic equipment, such as ballistic vests, helmets and other protection products, combat uniforms, and backpacks, as well as firearms accessories consisting of handgun holsters, magazine pouches, and slings. In addition, it is also involved in the lease of real estate properties; and trade of military materials. The company markets and sells its products under the Colt, CZ (Ceská zbrojovka), CZ-USA, Colt Canada, Dan Wesson, Brno Rifles, and 4M Systems brands. It sells its products for armed forces, military and law enforcement, personal defense, hunting, sport shooting, and other civilian uses. The company was formerly known as CZG - Ceská zbrojovka Group SE and changed its name to Colt CZ Group SE in April 2022. The company was founded in 1936 and is headquartered in Prague, the Czech Republic. Colt CZ Group SE is a subsidiary of Ceska Zbrojovka Partners SE.
Full CZGZF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.